Funding for this research was provided by:
Chief Scientist Office (ETM/47)
Diabetes UK (10/0004010)
Juvenile Diabetes Research Foundation United Kingdom (1-SRA-2016-333-M-R)
Helsinki University Hospital Research Funds
The Academy of Finland (275614)
The Wilhelm and Else Stockmann Foundation
Novo Nordisk Foundation
The Liv och Hälsa Society
Folkhälsan Research Foundation
Text and Data Mining valid from 2019-06-20
Received: 27 February 2019
Accepted: 30 April 2019
First Online: 20 June 2019
Duality of interest
: P-HG has received investigator research grants from Eli Lilly and Roche, and lecture honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, MSD, Novartis, Novo Nordisk and Sanofi. P-HG is an advisor for AbbVie, AstraZeneca, Boehringer Ingelheim, Cebix, Eli Lilly, Janssen, MSD, Novartis, Novo Nordisk and Sanofi.
: HMC receives research support and honorarium and is also a member of the advisory panels and speaker’s bureaus for Sanofi Aventis, Regeneron and Eli Lilly. HMC has been a member of Data and Safety Monitoring Board of the Advisory Panel for the CANTOS Trial (Novartis Pharmaceuticals). HMC also receives or has recently received a non-binding research support from Pfizer Inc. and AstraZeneca LP. HMC is a shareholder of Roche Pharmaceuticals and Bayer.
: RND is a shareholder of SpOtOn Clinical Diagnostics Ltd.
: MC, EV, SJM, NS, LAKB, DD, PMM and CF declare that there is no duality of interest associated with their contribution to this manuscript.